{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:32:06Z","timestamp":1763533926288},"reference-count":19,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Ceftazidime-avibactam and comparator antibiotics were tested by the broth microdilution method against 200\n Enterobacteriaceae<\/jats:named-content>\n and 25\n Pseudomonas aeruginosa<\/jats:named-content>\n strains resistant to fluoroquinolones (including strains with the extended-spectrum \u03b2-lactamase [ESBL] phenotype and ceftazidime-resistant strains) collected from our institution. The MICs and mechanisms of resistance to fluoroquinolone were also studied. Ninety-nine percent of fluoroquinolone-resistant\n Enterobacteriaceae<\/jats:named-content>\n strains were inhibited at a ceftazidime-avibactam MIC of \u22644 mg\/liter (using the susceptible CLSI breakpoint for ceftazidime alone as a reference). Ceftazidime-avibactam was very active against ESBL\n Escherichia coli<\/jats:named-content>\n (MIC\n 90<\/jats:sub>\n of 0.25 mg\/liter), ESBL\n Klebsiella pneumoniae<\/jats:named-content>\n (MIC\n 90<\/jats:sub>\n of 0.5 mg\/liter), ceftazidime-resistant AmpC-producing species (MIC\n 90<\/jats:sub>\n of 1 mg\/liter), non-ESBL\n E. coli<\/jats:named-content>\n (MIC\n 90<\/jats:sub>\n of \u22640.125 mg\/liter), non-ESBL\n K. pneumoniae<\/jats:named-content>\n (MIC\n 90<\/jats:sub>\n of 0.25 mg\/liter), and ceftazidime-nonresistant AmpC-producing species (MIC\n 90<\/jats:sub>\n of \u22640.5 mg\/liter). Ninety-six percent of fluoroquinolone-resistant\n P. aeruginosa<\/jats:named-content>\n strains were inhibited at a ceftazidime-avibactam MIC of \u22648 mg\/liter (using the susceptible CLSI breakpoint for ceftazidime alone as a reference), with a MIC\n 90<\/jats:sub>\n of 8 mg\/liter. Additionally, fluoroquinolone-resistant mutants from each species tested were obtained\n in vitro<\/jats:italic>\n from two strains, one susceptible to ceftazidime and the other a \u03b2-lactamase producer with a high MIC against ceftazidime but susceptible to ceftazidime-avibactam. Thereby, the impact of fluoroquinolone resistance on the activity of ceftazidime-avibactam could be assessed. The MIC\n 90<\/jats:sub>\n values of ceftazidime-avibactam for the fluoroquinolone-resistant mutant strains of\n Enterobacteriaceae<\/jats:named-content>\n and\n P. aeruginosa<\/jats:named-content>\n were \u22644 mg\/liter and \u22648 mg\/liter, respectively. We conclude that the presence of fluoroquinolone resistance does not affect\n Enterobacteriaceae<\/jats:named-content>\n and\n P. aeruginosa<\/jats:named-content>\n susceptibility to ceftazidime-avibactam; that is, there is no cross-resistance.\n <\/jats:p>","DOI":"10.1128\/aac.05136-14","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T02:03:07Z","timestamp":1425952987000},"page":"3059-3065","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Activity of Ceftazidime-Avibactam against Fluoroquinolone-Resistant Enterobacteriaceae and Pseudomonas aeruginosa"],"prefix":"10.1128","volume":"59","author":[{"given":"C.","family":"Pitart","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Clinic, School of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Cl\u00ednic-Universitat de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Marco","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Clinic, School of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Cl\u00ednic-Universitat de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. A.","family":"Keating","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Infection Innovative Medicines, Waltham, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. W.","family":"Nichols","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Infection Innovative Medicines, Waltham, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Vila","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Clinic, School of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Cl\u00ednic-Universitat de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-09"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.012"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70190-7"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.3.247"},{"key":"e_1_3_2_7_2","volume-title":"CLSI M100-S22","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/421495"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00666-11"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.6.743"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2477"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.491"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1201"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008029"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01722-10"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku025"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.07.005"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq306"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02429-13"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05136-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05136-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:08:08Z","timestamp":1645484888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05136-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1128\/AAC.05136-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.05136-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2014-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}